Treating Recurrent News Today

New data presented at ACG 2023 showed an approximate 60% success rate of recurrent C difficile prevention in adults with comorbid conditions including CKD and cardiac disease.

Despite initial promise, combining lenalidomide with cediranib didnt improve progression-free survival in differentiated thyroid cancer (DTC).

Joseph Reilly, BS, PharmD, BCGP, and Andrew Skinner, MD, discuss the potential benefits of using live-jslm early on to treat CDI, as well as the implications of this new treatment.